Examining the effects of extended-injectable buprenorphine for those using high potency synthetic opioids.
A Randomized Controlled Trial Examining Extended-Injectable Buprenorphine in those who use High Potency Synthetic Opioids
This study is looking at whether a long-lasting injection of buprenorphine can help people with opioid use disorder who are using strong synthetic opioids, by comparing their success in staying off drugs to those taking the usual sublingual buprenorphine/naloxone treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10808333 on NIH RePORTER |
What this research studies
This research investigates how extended-release injectable buprenorphine can help individuals with opioid use disorder (OUD) who are using high potency synthetic opioids (HPSO). The study aims to compare the rates of abstinence and relapse in patients receiving this treatment versus those using standard sublingual buprenorphine/naloxone. By analyzing individual responses to treatment and potential biomarkers, the research seeks to optimize medication-assisted treatment for this vulnerable population. Participants will be monitored for their physiological dependence and withdrawal symptoms throughout the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with opioid use disorder and are using high potency synthetic opioids.
Not a fit: Patients who do not use high potency synthetic opioids or are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients struggling with opioid use disorder related to high potency synthetic opioids.
How similar studies have performed: While there is limited research specifically on extended-injectable buprenorphine for high potency synthetic opioids, similar approaches have shown promise in improving treatment adherence for opioid use disorder.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Luba, Rachel R — Columbia University Health Sciences
- Study coordinator: Luba, Rachel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.